Current treatment options for psoriatic arthritis: spotlight on abatacept

References

• RitchlinCTColbertRAGladmanDDPsoriatic arthritisN Engl J Med20173761095797028273019
   PubMed Web of Science ®Google Scholar
• UrsiniFD’AngeloSRussoEComplement C3 is the strongest predictor of whole-body insulin sensitivity in psoriatic arthritisPLoS One2016119e016346427656896
   PubMed Web of Science ®Google Scholar
• UrsiniFGrembialeANatySGrembialeRDSerum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patientsClin Rheumatol201433121759176424005838
   PubMed Web of Science ®Google Scholar
• GelfandJMYeungHMetabolic syndrome in patients with psoriatic diseaseJ Rheumatol Suppl201289242822751586
   PubMedGoogle Scholar
• SchieirOTosevskiCGlazierRHHogg-JohnsonSBadleyEMIncident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysisAnn Rheum Dis20177681396140428219882
   PubMed Web of Science ®Google Scholar
• RitchlinCPsoriatic disease – from skin to boneNat Clin Pract Rheumatol200731269870618037929
   PubMedGoogle Scholar
• LemosLLde Oliveira CostaJAlmeidaAMTreatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safetyRheumatol Int201434101345136024728068
   PubMed Web of Science ®Google Scholar
• GiacomelliRAfeltraAAlunnoAInternational consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease managementAutoimmun Rev201716991192428705780
   PubMed Web of Science ®Google Scholar
• SkapenkoALeipeJLipskyPESchulze-KoopsHThe role of the T cell in autoimmune inflammationArthritis Res Ther20057Suppl 2S4S1415833146
   PubMed Web of Science ®Google Scholar
• OrbanTBundyBBeckerDJCostimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatmentDiabetes Care20143741069107524296850
   PubMed Web of Science ®Google Scholar
• LangfordCACuthbertsonDYtterbergSRA randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritisArthritis Rheumatol201769483784528133925
   PubMed Web of Science ®Google Scholar
• TjarnlundATangQWickCAbatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trialAnn Rheum Dis2018771556228993346
   PubMed Web of Science ®Google Scholar
• MeinersPMVissinkAKroeseFGAbatacept treatment reduces disease activity in early primary Sjogren’s syndrome (open-label proof of concept ASAP study)Ann Rheum Dis20147371393139624473674
   PubMed Web of Science ®Google Scholar
• MerrillJTBurgos-VargasRWesthovensRThe efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trialArthritis Rheum201062103077308720533545
   PubMed Web of Science ®Google Scholar
• LangfordCACuthbertsonDYtterbergSRA randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritisArthritis Rheumatol201769484685328133931
   PubMed Web of Science ®Google Scholar
• SandbornWJColombelJFSandsBEAbatacept for Crohn’s disease and ulcerative colitisGastroenterology201214316269 e422504093
   PubMed Web of Science ®Google Scholar
• KhourySJRochonJDingLACCLAIM: a randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosisMult Scler201723568669527481207
   PubMed Web of Science ®Google Scholar
• CoatesLCKavanaughAMeasePJGroup for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritisArthritis Rheumatol20166851060107126749174
   PubMed Web of Science ®Google Scholar
• GossecLSmolenJSRamiroSEuropean League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 updateAnn Rheum Dis201675349951026644232
   PubMed Web of Science ®Google Scholar
• ChenLFliesDBMolecular mechanisms of T cell co-stimulation and co-inhibitionNat Rev Immunol201313422724223470321
   PubMed Web of Science ®Google Scholar
• YamadaASalamaADSayeghMHThe role of novel T cell costimulatory pathways in autoimmunity and transplantationJ Am Soc Nephrol200213255957511805188
   PubMed Web of Science ®Google Scholar
• GreenJMKarpitskiyVKimzeySLShawASCoordinate regulation of T cell activation by CD2 and CD28J Immunol200016473591359510725714
   PubMed Web of Science ®Google Scholar
• LenschowDJWalunasTLBluestoneJACD28/B7 system of T cell costimulationAnnu Rev Immunol1996142332588717514
   PubMed Web of Science ®Google Scholar
• BerardMToughDFQualitative differences between naive and memory T cellsImmunology2002106212713812047742
   PubMed Web of Science ®Google Scholar
• PerkinsDWangZDonovanCRegulation of CTLA-4 expression during T cell activationJ Immunol199615611415441598666782
   PubMed Web of Science ®Google Scholar
• CaiYFlemingCYanJNew insights of T cells in the pathogenesis of psoriasisCell Mol Immunol20129430230922705915
   PubMed Web of Science ®Google Scholar
• HebertHLAliFRBowesJGriffithsCEBartonAWarrenRBGenetic susceptibility to psoriasis and psoriatic arthritis: implications for therapyBr J Dermatol2012166347448222050552
   PubMed Web of Science ®Google Scholar
• CostelloPJWinchesterRJCurranSAPsoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen drivenJ Immunol200116642878288611160357
   PubMed Web of Science ®Google Scholar
• CostelloPBresnihanBO’FarrellyCFitzGeraldOPredominance of CD8+ T lymphocytes in psoriatic arthritisJ Rheumatol19992651117112410332977
   PubMed Web of Science ®Google Scholar
• CurranSAFitzGeraldOMCostelloPJNucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigensJ Immunol200417231935194414734779
   PubMed Web of Science ®Google Scholar
• ArnettFCReveilleJDDuvicMPsoriasis and psoriatic arthritis associated with human immunodeficiency virus infectionRheum Dis Clin North Am199117159782041889
   PubMed Web of Science ®Google Scholar
• JosefowiczSZLuLFRudenskyAYRegulatory T cells: mechanisms of differentiation and functionAnnu Rev Immunol20123053156422224781
   PubMed Web of Science ®Google Scholar
• BettelliEKornTOukkaMKuchrooVKInduction and effector functions of T(H)17 cellsNature200845371981051105718563156
   PubMed Web of Science ®Google Scholar
• NoackMMiossecPTh17 and regulatory T cell balance in autoimmune and inflammatory diseasesAutoimmun Rev201413666867724418308
   PubMed Web of Science ®Google Scholar
• MenonBGullickNJWalterGJInterleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progressionArthritis Rheumatol20146651272128124470327
   PubMed Web of Science ®Google Scholar
• RaychaudhuriSPRaychaudhuriSKGenoveseMCIL-17 receptor and its functional significance in psoriatic arthritisMol Cell Biochem20123591–241942921894442
   PubMed Web of Science ®Google Scholar
• D’AngeloSTramontanoGGilioMLeccesePOlivieriIReview of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-respondersOpen Access Rheumatol20179212828280401
   PubMed Web of Science ®Google Scholar
• D’AngeloSCarrieroAGilioMUrsiniFLeccesePPalazziCSafety of treatment options for spondyloarthritis: a narrative reviewExpert Opin Drug Saf Epub2018 35
   Web of Science ®Google Scholar
• European Medicines Agency (EMA)Abatacept (Orencia) European public assessment report (EPAR) product information Updated August 9, 2017
   Google Scholar
• GenoveseMCCovarrubiasALeonGSubcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexateArthritis Rheum201163102854286421618201
   PubMed Web of Science ®Google Scholar
• HaggertyHGAbbottMAReillyTPEvaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritisJ Rheumatol200734122365237318050376
   PubMed Web of Science ®Google Scholar
• NashPNayiagerSGenoveseMCImmunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label studyArthritis Care Res2013655718728
   PubMed Web of Science ®Google Scholar
• WesthovensRRoblesMXimenesACClinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factorsAnn Rheum Dis200968121870187719124524
   PubMed Web of Science ®Google Scholar
• EmeryPBurmesterGRBykerkVPEvaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment periodAnn Rheum Dis2015741192625367713
   PubMed Web of Science ®Google Scholar
• KremerJMGenantHKMorelandLWEffects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trialAnn Intern Med20061441286587616785475
   PubMed Web of Science ®Google Scholar
• GenoveseMCBeckerJCSchiffMAbatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibitionN Engl J Med2005353111114112316162882
   PubMed Web of Science ®Google Scholar
• SchiffMPritchardCHuffstutterJEThe 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trialAnn Rheum Dis200968111708171419074911
   PubMed Web of Science ®Google Scholar
• KremerJMRussellASEmeryPLong-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trialAnn Rheum Dis201170101826183021893583
   PubMed Web of Science ®Google Scholar
• WeinblattMEMorelandLWWesthovensRSafety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial programJ Rheumatol201340678779723588946
   PubMed Web of Science ®Google Scholar
• SalliotCDougadosMGossecLRisk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trialsAnn Rheum Dis2009681253218203761
   PubMed Web of Science ®Google Scholar
• SimonTASmittenALFranklinJMalignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessmentAnn Rheum Dis200968121819182619054822
   PubMed Web of Science ®Google Scholar
• KangEHJinYBrillGComparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort studyJ Am Heart Assoc201873e00739329367417
   PubMed Web of Science ®Google Scholar
• D’AngeloSTGGilioMAbignanoGAbatacept in patients with inflammatory chronic arthritis and demyelinating disorders: case series and systematic literature reviewSubmitted article2018
   Google Scholar
• UrsiniFLeporiniCBeneFAnti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysisSci Rep201771534628706194
   PubMed Web of Science ®Google Scholar
• UrsiniFRussoELetizia HribalMAbatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational studyMedicine20159421e88826020396
   PubMed Web of Science ®Google Scholar
• UrsiniFRussoERuscittiPGiacomelliRDe SarroGThe effect of non-TNF-targeted biologics and small molecules on insulin resistance in inflammatory arthritisAutoimmun Rev201817439940429452240
   PubMed Web of Science ®Google Scholar
• UrsiniFNatySRussoEGrembialeRDAbatacept in psoriatic arthritis: case report and short reviewJ Pharmacol Pharmacother20134Suppl 1S29S3224347977
   PubMedGoogle Scholar
• AltmeyerMDKerisitKGBohEETherapeutic hotline. Abatacept: our experience of use in two patients with refractory psoriasis and psoriatic arthritisDermatol Ther201124228729021410619
   PubMed Web of Science ®Google Scholar
• RodriguesCEVieiraFJCalladoMRGomesKWde AndradeJEVieiraWPUse of the abatacept in a patient with psoriatic arthritisRev Bras Reumatol201050334034521125170
   PubMedGoogle Scholar
• VieiraFJCalladoMRVieiraWPAbatacept as an option therapy in difficult to treat psoriatic arthritisRheumatol Int201030684985019579026
   PubMed Web of Science ®Google Scholar
• MeasePGenoveseMCGladsteinGAbatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialArthritis Rheum201163493994821128258
   PubMed Web of Science ®Google Scholar
• MeasePJGottliebABvan der HeijdeDEfficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritisAnn Rheum Dis20177691550155828473423
   PubMed Web of Science ®Google Scholar
• ScheinfeldNAlefacept: a safety profileExpert Opin Drug Saf20054697598516255657
   PubMedGoogle Scholar
• MengYDongmeiLYanbinPSystematic review and meta-analysis of ustekinumab for moderate to severe psoriasisClin Exp Dermatol201439669670725039593
   PubMed Web of Science ®Google Scholar
• SzentpeteryAHeffernanEGogartyMAbatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritisArthritis Res Ther201719115828679449
   PubMed Web of Science ®Google Scholar
• IannoneFLapadulaGThe inhibitor of costimulation of T cells: abataceptJ Rheumatol Suppl20128910010222751606
   PubMedGoogle Scholar
• SchiffMSubcutaneous abatacept for the treatment of rheumatoid arthritisRheumatology201352698699723463804
   PubMed Web of Science ®Google Scholar